Engagement in human immunodeficiency virus care: linkage, retention, and antiretroviral therapy adherence

Ellen F Eaton; Michael S Saag; Michael Mugavero

doi:10.1016/j.idc.2014.06.004

Engagement in human immunodeficiency virus care: linkage, retention, and antiretroviral therapy adherence

Infect Dis Clin North Am. 2014 Sep;28(3):355-69. doi: 10.1016/j.idc.2014.06.004.

Authors

Ellen F Eaton¹, Michael S Saag², Michael Mugavero³

Affiliations

¹ Division of Infectious Disease, University of Alabama, Birmingham, 229 Tinsley Harrison Tower, 1900 University Boulevard, Birmingham, AL 35223, USA. Electronic address: eeaton@uab.edu.
² Division of Infectious Disease, University of Alabama, Birmingham, 229 Tinsley Harrison Tower, 1900 University Boulevard, Birmingham, AL 35223, USA.
³ Division of Infectious Disease, University of Alabama, Birmingham, BBRB 206H, 845 19th Street South, Birmingham, AL 35223, USA.

PMID: 25151561
DOI: 10.1016/j.idc.2014.06.004

Abstract

Effective human immunodeficiency virus (HIV) care in the modern antiretroviral therapy (ART) era requires early entry into and retention in care. Early initiation and adherence to ART therapy improves outcomes. Many evidence-based tools and behavioral interventions are available to optimize adherence to care and ART and can be implemented in clinical settings. Monitoring care engagement and ART adherence creates the opportunity to intervene and prevent virologic failure or loss to follow up. Special HIV-infected populations, such as pregnant and mentally ill patients, require enhanced surveillance and care.

Keywords: Adherence monitoring; Human immunodeficiency virus retention; Linkage to care.

Publication types

Review

MeSH terms

Antiretroviral Therapy, Highly Active / methods*
Behavior Therapy / methods*
HIV Infections / diagnosis*
HIV Infections / drug therapy*
Humans
Lost to Follow-Up
Medication Adherence*

Grants and funding

HS013852/HS/AHRQ HHS/United States